XML 67 R46.htm IDEA: XBRL DOCUMENT v3.6.0.2
Business Combination - Additional Information (Details) - USD ($)
3 Months Ended 12 Months Ended
Sep. 20, 2016
Dec. 31, 2016
Sep. 30, 2016
Dec. 31, 2016
Business Acquisition [Line Items]        
Goodwill impairment       $ 0
Transaction costs incurred in relation to business combination       2,500,000
Viventia Bio Inc.        
Business Acquisition [Line Items]        
Shares of common stock issued to the selling shareholders 4,013,431      
Percentage of voting interests acquired (as a percent) 19.90%      
Shares of common stock deposited into an escrow Account per acquiree 401,343      
Percentage of common stock owned by acquiree at closing of the share purchase agreement 10.00%      
Number of shares issued in business combination (in shares) 4,013,431      
Value of shares issued $ 13,500,000      
Consideration transferred using discounted cash flow estimate 46,200,000      
Fair value of consideration transferred $ 59,700,000      
Deferred tax liability   $ 16,335,000 $ 9,774,000 16,335,000
Revenue recognized in a business combination   0    
Operating loss incurred in relation to business combination   3,500,000    
Transaction costs incurred in relation to business combination     $ 2,500,000  
IPR&D        
Business Acquisition [Line Items]        
Impairment related to IPR&D       $ 0
Unobservable Inputs (Level 3) | Discounted Cash Flow Approach | Proxinium IPR&D        
Business Acquisition [Line Items]        
Discount rate (in percentage)       26.10%
Unobservable Inputs (Level 3) | Minimum | Discounted Cash Flow Approach        
Business Acquisition [Line Items]        
Discount rate (in percentage)       8.60%
Unobservable Inputs (Level 3) | Maximum | Discounted Cash Flow Approach        
Business Acquisition [Line Items]        
Discount rate (in percentage)       13.70%
United States | Unobservable Inputs (Level 3) | Discounted Cash Flow Approach | Vicinium IPR&D        
Business Acquisition [Line Items]        
Cost of development for the aseet   48,000,000   $ 48,000,000
European Union | Unobservable Inputs (Level 3) | Discounted Cash Flow Approach | Vicinium IPR&D        
Business Acquisition [Line Items]        
Cost of development for the aseet   25,000,000   25,000,000
R.O.W. | Unobservable Inputs (Level 3) | Discounted Cash Flow Approach | Vicinium IPR&D        
Business Acquisition [Line Items]        
Cost of development for the aseet   $ 25,000,000   $ 25,000,000
Viventia Bio Inc.        
Business Acquisition [Line Items]        
Period during which quarterly earn-outs are payable after date of net sales 15 years      
Period in which acquiree is to use commercially reasonable efforts to achieve marketing authorizations 7 years      
Collaborative Arrangement, Revenue based on Specified Milestone [Member] | Viventia Bio Inc. | Vicinium        
Business Acquisition [Line Items]        
Percentage of net sales of quarterly earn-out payments during earn-out periods 2.00%      
Collaborative Arrangement, Revenue based on Specified Milestone [Member] | Viventia Bio Inc. | United States | Vicinium        
Business Acquisition [Line Items]        
One-time milestone payment upon first sale of product $ 12,500,000      
Collaborative Arrangement, Revenue based on Specified Milestone [Member] | Viventia Bio Inc. | Europe | Vicinium        
Business Acquisition [Line Items]        
One-time milestone payment upon first sale of product 7,000,000      
Collaborative Arrangement, Revenue based on Specified Milestone [Member] | Viventia Bio Inc. | Japan | Vicinium        
Business Acquisition [Line Items]        
One-time milestone payment upon first sale of product $ 3,000,000